Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder

被引：83
作者：
Goddard, Andrew W. [1 ]
Shekhar, Anantha [1 ]
Whiteman, Aaron F. [2 ]
McDougle, Christopher J. [1 ]
机构：
[1] Indiana Univ, Sch Med, Dept Psychiat, Univ Hosp,UH3124, Indianapolis, IN 46202 USA
[2] Fairbanks Hosp, Clearvista Recovery Associates, Indianapolis, IN 46256 USA
来源：
DRUG DISCOVERY TODAY | 2008年 / 13卷 / 7-8期
关键词：
D O I：
10.1016/j.drudis.2007.12.009
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Obsessive-compulsive disorder (OCD) is a disabling psychiatric condition affecting 1-2% of the community. Although modern drug, behavioral and psychosurgical therapies have improved the prognosis of OCD considerably, approximately 30% of patients remain treatment-refractory. Currently, selective serotonin (5-HT) reuptake inhibitors (SSRIs) are the drug treatments of choice for OCD. Accordingly, this review evaluates the evidence for a role of the serotonin (5-HT) neurochemical system in the treatment and pathophysiology of OCD. However, drug treatment approaches that modify function of interrelated neurochemical systems, such as the dopamine and glutamate systems, are also briefly discussed as they promise to complement and enhance SSRI treatment effects.
引用
收藏
页码：325 / 332
页数：8
相关论文
共 93 条
[1]   Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder [J].
Arnold, Paul Daniel ;
Sicard, Tricia ;
Burroughs, Eliza ;
Richter, Margaret A. ;
Kennedy, James L. .
ARCHIVES OF GENERAL PSYCHIATRY, 2006, 63 (07) :769-776
[2]   Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study [J].
Atmaca, M ;
Kuloglu, M ;
Tezcan, E ;
Gecici, O .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 (03) :115-119
[3]  
BARR LC, 1994, ARCH GEN PSYCHIAT, V51, P309
[4]   An autistic dimension - A proposed subtype of obsessive-compulsive disorder [J].
Bejerot, Susanne .
AUTISM, 2007, 11 (02) :101-110
[5]   Association of the serotonin transporter promoter regulatory region polymorphism and obsessive-compulsive disorder [J].
Bengel, D ;
Greenberg, BD ;
Corá-Locatelli, G ;
Altemus, M ;
Heils, A ;
Li, Q ;
Murphy, DL .
MOLECULAR PSYCHIATRY, 1999, 4 (05) :463-466
[6]   Effect of atypical antipsychotic drugs on 5-HT2 receptors in the rat orbito-frontal cortex:: an in vivo electrophysiological study [J].
Bergqvist, PBF ;
Dong, JM ;
Blier, P .
PSYCHOPHARMACOLOGY, 1999, 143 (01) :89-96
[7]   Lack of effects on core obsessive-compulsive symptoms of tryptophan depletion during symptom provocation in remitted obsessive-compulsive disorder patients [J].
Berney, A ;
Sookman, D ;
Leyton, M ;
Young, SN ;
Benkelfat, C .
BIOLOGICAL PSYCHIATRY, 2006, 59 (09) :853-857
[8]   Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene [J].
Billett, EA ;
Richter, MA ;
King, N ;
Heils, A ;
Lesch, KP ;
Kennedy, JL .
MOLECULAR PSYCHIATRY, 1997, 2 (05) :403-406
[9]   The importance of serotonin and noradrenaline in anxiety [J].
Blier, Pierre ;
El Mansari, Mostafa .
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2007, 11 :16-23
[10]   Pharmacotherapies in the management of obsessive-compulsive disorder [J].
Blier, Pierre ;
Habib, Rami ;
Flament, Martine F. .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2006, 51 (07) :417-430
12345678910